MX2022012310A - Metodos para tratar la esclerosis multiple recidivante con un inhibidor de tirosina quinasa de bruton. - Google Patents
Metodos para tratar la esclerosis multiple recidivante con un inhibidor de tirosina quinasa de bruton.Info
- Publication number
- MX2022012310A MX2022012310A MX2022012310A MX2022012310A MX2022012310A MX 2022012310 A MX2022012310 A MX 2022012310A MX 2022012310 A MX2022012310 A MX 2022012310A MX 2022012310 A MX2022012310 A MX 2022012310A MX 2022012310 A MX2022012310 A MX 2022012310A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- multiple sclerosis
- bruton
- inhibitor
- tyrosine kinase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063005095P | 2020-04-03 | 2020-04-03 | |
| US202063051767P | 2020-07-14 | 2020-07-14 | |
| PCT/US2021/025301 WO2021202825A1 (en) | 2020-04-03 | 2021-04-01 | Methods of treating relapsing multiple sclerosis using an inhibitor of bruton's tyrosine kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022012310A true MX2022012310A (es) | 2022-10-27 |
Family
ID=75625678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022012310A MX2022012310A (es) | 2020-04-03 | 2021-04-01 | Metodos para tratar la esclerosis multiple recidivante con un inhibidor de tirosina quinasa de bruton. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12605376B2 (https=) |
| EP (1) | EP4125906A1 (https=) |
| JP (1) | JP2023520469A (https=) |
| KR (1) | KR20220163986A (https=) |
| CN (1) | CN115916205A (https=) |
| AU (1) | AU2021249129A1 (https=) |
| BR (1) | BR112022019846A2 (https=) |
| CA (1) | CA3177390A1 (https=) |
| CL (1) | CL2022002699A1 (https=) |
| IL (1) | IL296990A (https=) |
| MX (1) | MX2022012310A (https=) |
| TW (1) | TWI907406B (https=) |
| WO (1) | WO2021202825A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021173740A1 (en) * | 2020-02-28 | 2021-09-02 | Genentech, Inc. | Methods of treating primary progressive multiple sclerosis using an inhibitor of bruton's tyrosine kinase |
| WO2022240920A1 (en) | 2021-05-14 | 2022-11-17 | Loxo Oncology, Inc. | Cocrystalline forms of a bruton's tyrosine kinase inhibitor |
| CN114028393B (zh) * | 2021-11-07 | 2023-07-18 | 天津医科大学 | 阿帕替尼在制备治疗多发性硬化症药物的用途 |
| TW202508592A (zh) * | 2023-05-16 | 2025-03-01 | 美商建南德克公司 | 使用布魯頓酪胺酸激酶之抑制劑來治療復發型多發性硬化症之方法 |
| WO2025264860A2 (en) | 2024-06-18 | 2025-12-26 | Yale University | Methods of treating post-covid airway disease |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| KR20170033358A (ko) | 2014-08-07 | 2017-03-24 | 파마싸이클릭스 엘엘씨 | 브루톤 티로신 키나아제 저해제의 신규한 제제 |
| WO2017148837A1 (en) | 2016-02-29 | 2017-09-08 | F. Hoffmann-La Roche Ag | Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase |
| CN107043366B (zh) | 2017-04-25 | 2020-05-26 | 中国药科大学 | 4-氨基嘧啶类化合物、其制备方法及医药用途 |
| KR102635949B1 (ko) | 2017-05-18 | 2024-02-14 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 종양 치료용 약물의 제조에 있어서의 ezh2 억제제 및 btk 억제제의 조합물의 용도 |
| WO2019208805A1 (ja) * | 2018-04-27 | 2019-10-31 | 小野薬品工業株式会社 | Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤 |
| EP3849559A4 (en) * | 2018-09-12 | 2022-06-01 | Denovo Biopharma LLC | COMBINATION OF ENZASTAURIN AND INHIBITORS OF BTK AND USES THEREOF |
| TW202042815A (zh) | 2019-01-22 | 2020-12-01 | 美商建南德克公司 | 使用布魯頓（bruton）酪胺酸激酶抑制劑治療類風性關節炎、慢性自發性蕁麻疹及全身性紅斑性狼瘡的方法 |
| WO2021173740A1 (en) | 2020-02-28 | 2021-09-02 | Genentech, Inc. | Methods of treating primary progressive multiple sclerosis using an inhibitor of bruton's tyrosine kinase |
-
2021
- 2021-04-01 BR BR112022019846A patent/BR112022019846A2/pt unknown
- 2021-04-01 JP JP2022559934A patent/JP2023520469A/ja active Pending
- 2021-04-01 US US17/995,259 patent/US12605376B2/en active Active
- 2021-04-01 IL IL296990A patent/IL296990A/en unknown
- 2021-04-01 CA CA3177390A patent/CA3177390A1/en active Pending
- 2021-04-01 MX MX2022012310A patent/MX2022012310A/es unknown
- 2021-04-01 AU AU2021249129A patent/AU2021249129A1/en active Pending
- 2021-04-01 TW TW110112266A patent/TWI907406B/zh active
- 2021-04-01 CN CN202180035499.8A patent/CN115916205A/zh active Pending
- 2021-04-01 EP EP21720649.9A patent/EP4125906A1/en active Pending
- 2021-04-01 KR KR1020227037384A patent/KR20220163986A/ko active Pending
- 2021-04-01 WO PCT/US2021/025301 patent/WO2021202825A1/en not_active Ceased
-
2022
- 2022-09-30 CL CL2022002699A patent/CL2022002699A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4125906A1 (en) | 2023-02-08 |
| TW202203925A (zh) | 2022-02-01 |
| CA3177390A1 (en) | 2021-10-07 |
| US20230149395A1 (en) | 2023-05-18 |
| BR112022019846A2 (pt) | 2022-11-22 |
| AU2021249129A1 (en) | 2022-10-20 |
| CN115916205A (zh) | 2023-04-04 |
| WO2021202825A1 (en) | 2021-10-07 |
| CL2022002699A1 (es) | 2023-03-31 |
| JP2023520469A (ja) | 2023-05-17 |
| IL296990A (en) | 2022-12-01 |
| TWI907406B (zh) | 2025-12-11 |
| US12605376B2 (en) | 2026-04-21 |
| KR20220163986A (ko) | 2022-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022012310A (es) | Metodos para tratar la esclerosis multiple recidivante con un inhibidor de tirosina quinasa de bruton. | |
| MX2025005489A (es) | Uso de lumateperona para el tratamiento del trastorno bipolar ii | |
| ZA202306172B (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| CZ309247B6 (cs) | 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru | |
| EP1933833B8 (en) | Therapy for the treatment of overactive bladder | |
| MX2024013020A (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| CR20240514A (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| MX2024014626A (es) | Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton | |
| EP4520398A3 (en) | Treatment of prostate cancer | |
| FI3972603T3 (fi) | Menetelmiä sjögrenin oireyhtymän hoitamiseksi käyttäen brutonin tyrosiinikinaasin estäjää | |
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| AU2018282105A1 (en) | Dosing of vibegron for treatment of overactive bladder | |
| AU2021322255A8 (en) | Use of dexpramipexole for the treatment of moderate to severe asthma | |
| MX2025008009A (es) | Moduladores de la proteolisis de bcl6 y metodos de uso asociados | |
| MX2022010513A (es) | Metodos para tratar esclerosis multiple progresiva primaria usando un inhibidor de tirosina quinasa de bruton. | |
| WO2021242844A8 (en) | Grk2 inhibitors and uses thereof | |
| WO2021239928A3 (en) | Treatment of cardiometabolic disease with inhibitors of type i interferon signalling | |
| PH12021551975A1 (en) | Use of vibegron to treat overactive bladder | |
| EE200300129A (et) | Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine | |
| TW200503666A (en) | Treatment of type 1 diabetes with pde5 inhibitors | |
| MX2025000582A (es) | Inhibidores de tirosina cinasa 2 y usos de estos | |
| ZA202407245B (en) | Novel use of pitolisant for treating severe fatigue | |
| MX2022007304A (es) | Uso de lemborexant para tratamiento del insomnio. | |
| WO2020232330A8 (en) | Inhibiting agents for bruton's tyrosine kinase | |
| PT1259229E (pt) | Utilizacao de benzotieno-[2,3-d]-pirimidinas com uma accao inibidora da pde v no tratamento do disfuncao erectil |